Holen Sie sich die Stockscreener-App
11.20
3.47%
0.375
Vorhandelsmarkt:
11.14
-0.055
-0.49%
Schlusskurs vom Vortag:
$10.82
Offen:
$10.76
24-Stunden-Volumen:
2.05M
Relative Volume:
1.24
Marktkapitalisierung:
$3.52B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-16.45
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+9.22%
1M Leistung:
+7.75%
6M Leistung:
+40.46%
1J Leistung:
+31.86%
1-Tages-Spanne:
$10.68
$11.20
1-Wochen-Bereich:
$9.99
$11.20
52-Wochen-Spanne:
$6.685
$11.20
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
11.20 | 3.40B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Multi asset correlation models including Amneal Pharmaceuticals Inc.Quarterly Trade Review & AI Driven Stock Movement Reports - newser.com
Will Amneal Pharmaceuticals Inc. stock outperform Dow Jones indexJuly 2025 Volume & Fast Exit and Entry Strategy Plans - newser.com
BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces - BioSpace
Is Amneal Pharmaceuticals Inc. stock ready for a breakoutWeekly Trade Recap & Intraday High Probability Alerts - newser.com
Candlestick signals on Amneal Pharmaceuticals Inc. stock todayJuly 2025 Movers & Daily Stock Trend Reports - newser.com
Will Amneal Pharmaceuticals Inc. stock benefit from automationJuly 2025 Earnings & Fast Moving Stock Watchlists - newser.com
Real time breakdown of Amneal Pharmaceuticals Inc. stock performanceWeekly Gains Summary & Safe Capital Allocation Plans - newser.com
How high can Amneal Pharmaceuticals Inc. stock goInsider Buying & Weekly Watchlist for Consistent Profits - newser.com
What analyst consensus says on Amneal Pharmaceuticals Inc. stockWeekly Trend Summary & Community Consensus Stock Picks - newser.com
Is Amneal Pharmaceuticals Inc. stock resilient to inflationPortfolio Risk Report & Weekly Chart Analysis and Trade Guides - newser.com
Is Amneal Pharmaceuticals Inc. stock a top momentum play2025 Trading Volume Trends & Real-Time Market Trend Scan - newser.com
Does Amneal Pharmaceuticals Inc. show high probability of rebound2025 Technical Overview & Real-Time Stock Movement Alerts - newser.com
Will Amneal Pharmaceuticals Inc. stock reach Wall Street targetsEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
How to manage a losing position in Amneal Pharmaceuticals Inc.Weekly Investment Report & Verified Stock Trade Ideas - newser.com
Amneal Pharmaceuticals Reports Strong Q3 2025 Results - MSN
Amneal Pharmaceuticals Hits New 52-Week High of $10.70 - Markets Mojo
Piper Sandler Reaffirms Overweight Rating for Amneal Pharmaceuticals (NASDAQ:AMRX) - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Option Care Health (OPCH) and Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal raises 2025 EPS guidance and outlines $300M–$500M CREXONT sales target as portfolio expansion accelerates - MSN
Amneal Pharmaceuticals stock hits 52-week high at $10.72 By Investing.com - Investing.com Australia
Amneal Pharmaceuticals (AMRX): One-Off $55.9M Loss Tests Bull Case Built on High Earnings Growth Forecasts - Sahm
Amneal Pharmaceuticals, Inc. (AMRX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Why Amneal (AMRX) Stock Is Up Today - Yahoo Finance
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High on Strong Earnings - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $10.72 - Investing.com
Truist Raises Price Target on Amneal Pharmaceuticals to $14 From $13, Keeps Buy Rating - MarketScreener
Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance - MarketBeat
Published on: 2025-10-31 02:59:36 - newser.com
Amneal Pharmaceuticals (AMRX) Profitability Milestone Tests Investor Optimism on Growth and Valuation - Yahoo Finance
Amneal Pharmaceuticals Q3 2025 Earnings Preview - MSN
Amneal: Q3 Earnings Snapshot - CT Insider
Amneal Pharmaceuticals Inc (AMRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Amneal Q3 2025 slides: Revenue up 12% as specialty products gain traction - Investing.com Canada
How Amneal Pharmaceuticals’ (AMRX) Return to Profitability and Respiratory Product Wins Have Changed Its Investment Story - simplywall.st
Amneal raises 2025 guidance and targets $300M–$500M peak CREXONT sales as new launches accelerate - MSN
Earnings call transcript: Amneal Pharma Q3 2025 beats EPS forecast, stock rises - Investing.com
Amneal Pharmaceuticals, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:AMRX) 2025-10-30 - Seeking Alpha
Amneal (AMRX) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Amneal Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals, Inc. (AMRX) Q3 FY2025 earnings call transcript - Yahoo Finance
Amneal Pharmaceuticals Outperforms Expectations And Raises Its Full-Year Outlook - Finimize
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Amneal Pharmaceuticals Q3 Adjusted Earnings, Revenue Rise; 2025 EPS Outlook Raised - MarketScreener
Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2025 - MarketScreener
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.35%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):